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Abstract: Drug delivery by means of transdermal patches raised great interest as a non-invasive
and sustained therapy. The present research aimed to design a patch for transdermal delivery of
melatonin, which was encapsulated in polycaprolactone (PCL) nanoparticles (NPs) by employing
flash nanoprecipitation (FNP) technique. Melatonin-loaded PCL nanoparticles were successfully
prepared with precise control of the particle size by effectively tuning process parameters. The effect
of process parameters on the particle size was assessed by dynamic light scattering for producing
particles with suitable size for transdermal applications. Quantification of encapsulated melatonin
was performed by mean of UV spectrophotometry, obtaining the estimation of encapsulation
efficiency (EE%) and loading capacity (LC%). An EE% higher than 80% was obtained. Differential
scanning calorimetry (DSC) analysis of NPs was performed to confirm effective encapsulation in the
solid phase. Cotton fabrics, functionalized by imbibition with the nano-suspension, were analyzed
by scanning electron microscopy to check morphology, adhesion and distribution of the NPs on the
surface; melatonin transdermal release from the functionalized fabric was performed via Franz’s cells
by using a synthetic membrane. NPs were uniformly distributed on cotton fibres, as confirmed by
SEM observations; the release test showed a continuous and controlled release whose kinetics were
satisfactorily described by Baker–Lonsdale model.
Keywords: textile; cotton; melatonin; nanoparticles; drug delivery; Franz cell; PCL; DSC;
flash nanoprecipitation (FNP); pharmaceutical nanotechnology
1. Introduction
Skin is the largest tissue of the human body (about two square meters) and accomplishes different
important roles, such as body protection from external factors (i.e., pathogenic agents) [1]. Furthermore,
skin has been used for several decades as route of administration for both local and systemic
drugs. In accordance to Food and Drug Administration (FDA), the former case is defined topical
administration and consists in the application of a drug to a particular spot on the outer surface of the
body; the latter is defined transdermal administration and involves the delivery through the dermal
layer of the skin to the systemic circulation by diffusion. Notwithstanding the numerous advantages in
using skin for topical and transdermal drug delivery, skin administration of several compounds is still
a challenging issue, due to the structural complexity of the skin barrier [2]. Nowadays, nanotechnology
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provides a promising solution to overcome this problem [3]. Biofunctional textiles [4]—a new
class of materials based on the combination of conventional textiles with advanced drug delivery
systems [5]—have brought about significant improvements in the transdermal administration of
active molecules [6,7]. Among biofunctional textiles, innovative transdermal patches have gained
considerable attention, due to the possibility to improve the performance of these devices by their
functionalization with nanocarrier-based drug delivery systems [5,8]. Transdermal patches aim at
improving drug permeation through the skin barrier, reaching blood circulation. This approach ensures
a sustained and constant drug release, with non-invasive delivery, reducing drug toxicity.
Biofunctional textiles composed by natural fabrics have been attracting much interest because
of their improved compatibility, which opens new utilizations in the biomedical field. Moreover,
natural fibers are largely available, biodegradable, and represent renewable resources in comparison
with synthetic fibers. For all the above mentioned advantages, cotton is a natural cellulosic fiber
widely used in the preparation of biofunctional textile [9,10]. However direct immobilization of an
active compound onto the fabrics surface may cause some drawbacks such as scarce skin penetration
or alteration of drug activity; for this reason many authors proposed to encapsulate the drug in a
nanocarrier prior to the functionalization of the textile material [5,11].
Nanocarriers represent one of the most studied transdermal drug delivery system [12,13].
Polymeric nanoparticles are among the most studied nanocarriers for drug delivery application,
since they have shown superior bioavailability and encapsulation yield; moreover, they can
delivery effectively therapeutic dose while minimizing side effects [14]. The polymeric materials
must fulfill specific requirements such as being non-toxic, biocompatible and biodegradable [15].
The list of polymers with such characteristics includes poly-lactide-co-glycolide, polylactic acid,
poly-ε-caprolactone, chitosan and gelatin [16].
Poly-ε-caprolactone (PCL) is a synthetic polymer that, thanks to its intrinsic biocompatibility and
biodegradability, is widely exploited in several biomedical applications such as tissue engineering,
implantable devices and nanomedicine [17,18]. PCL is mainly biodegraded in body fluids by cleavage
of the ester bond. The degradation mechanism consists in a first step in which PCL molecular weight
decreases due to chain scission and a second one where an actual weight loss is observable; the overall
biodegradation process can take up to one year to be completed and this makes PCL suitable for a
wide range of applications requiring long lasting releases [19]. Due to its versatility as drug carrier,
poly-ε-caprolactone has also been investigated for the transdermal route [20,21].
Concerning the production of PCL nanoparticles, a wide range of techniques are currently used
at research level. These methods include solvent evaporation [22], double emulsion [23], emulsion
polymerization [24], spray drying [25], and solvent displacement [26]. Among the above mentioned
technologies, a particular version of the solvent-displacement approach called flash nanoprecipitation
(FNP) [27] has garnered interest in terms of reproducibility and control, two key factors for scale-up to
industrial production [28].
In nanoprecipitation the preformed polymer is solubilized in a suitable organic solvent, and the
polymeric solution is then mixed with an anti-solvent in which the polymer is not soluble; the mixing
of the two liquid results in polymer precipitation in nanoparticle form [29]. The mixing condition is a
key factor in controlling nanoparticle formation; for this reason micro-mixers and micro-reactors are
used, especially when fast phenomena are occurring [27]. Micro-mixers are systems with characteristic
length scale from 1 to 1000 µm in which it is possible to achieve fast homogenization of the two streams
and good control of process parameters; Confined Impinging Jets Mixers (CIJM), in particular, have
been tested in several experimental works to produce polymeric nanoparticles [30–34]. Moreover,
many modelling studies have been conducted in order to understand the dynamics of FNP in CIJM
and this makes this technique sound from the point of view of process control [35–37].
It has been shown that FNP is an effective technique to encapsulate drugs of different type
such has menthol [33], curcumin [38], paclitaxel [39] and vitamin E [40]; these active principles are
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characterized by a marked hydrophobic behavior (LogP > 3.2, where P, partition-coefficient is the ratio
of concentrations of a compound in a mixture of two immiscible phases at equilibrium).
Generally speaking, the difficulties encountered in encapsulating hydrophilic substances are
considered one of the weaknesses of FNP technique [41], while recent studies are tackling the issue of
employing FNP to encapsulate more hydrophilic substances (LogP < 1.6) [42–44].
Among the numerous active pharmaceutical ingredients with a degree of hydrophilicity suitable
for encapsulation by FNP, melatonin (LogP = 1.6) is of particular interest in the field of bio functional
textiles [5]. Melatonin (MEL) is an hormone produced by the pineal gland, regulating the circadian
rhythm in mammals [45]. Traditionally, melatonin is orally administered to enhance daytime
sleep quality and reduce jet lag. Moreover, it is claimed to possess analgesic, anti-oxidative and
anti-inflammatory effects [13]. Despite the conventional administration route of melatonin being the
oral one, this involves several drawbacks affecting its efficiency. For instance, the oral fast-release,
followed by scarce bioavailability due to first pass metabolism, affects the duration of efficient
melatonin plasma levels decreasing the sleep-promoting effect. Moreover, the relatively high oral
dose of melatonin can cause the receptors desensitization, leading to tolerance insurgence [46].
In order to overcome these limitations, alternative administration routes for melatonin are under
investigation. Melatonin has been indicated as a good candidate for transdermal drug delivery in
numerous investigations [47,48], proposing skin as successful alternative to the oral route.
The present research work aimed at the development of an innovative patch for transdermal
delivery of melatonin. Given the necessity to enhance skin penetration and preserve bioactivity of
melatonin, it was decided to encapsulate it in a polymeric nanoparticles system that could penetrate
the skin outer layer and slowly release the drug in the inner one. For this reason it was decided
to incorporate MEL in PCL nanoparticles by using a simple and scalable approach such as FNP.
Firstly, melatonin-loaded nanoparticles were produced in CIJM, then a careful characterization
of the drug-loaded system was performed, in order to determine its features, such as sizes and
loading capacity, estimating the encapsulation efficiency of the process. Secondly, cotton fabrics were
functionalized by imbibition and their morphology was observed via scanning electron microscopy.
In conclusion, melatonin delivery from the functional fabric was assessed by Franz’s cell release test.
2. Materials and Methods
2.1. Materials
All chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA). Melatonin was in
powder form with assay ≥98%, PCL flakes with an average molecular weight of 14,000 Da were
used. Acetone with purity ≥99.5% meeting European Pharmacopedia standards was employed
as solvent. Phosphate buffer solution was prepared by using the following salts: sodium chloride
anhydrous ≥99%, potassium chloride ACS grade ≥99.5%, sodium phosphate dibasic dehydrate ≥99%
and potassium dihydrogen phosphate ACS reagent ≥99%. Ultrapure water was produced by mean
of a Milli-Q RG system by Millipore R (Billerica, MA, USA) and used in all experiments. The skin
mimicking membrane for the Franz diffusion cell was made of mixed cellulose esters with 0.45 µm
pore size, purchased from Whatman knitted cotton fabrics (100% cotton, Nm 30/1, single jersey) were
kindly gifted by Eusebio S.p.A (Crugnola di Mornago (VA), Italy). The fabrics were scoured at 95 ◦C
for 30 min in a 4 mg/mL Na2CO3 water solution and rinsed under tap water for 10 min to remove
impurities and waxes.
2.2. Nanoparticles Preparation
The nanoparticles were prepared by the flash nanoprecipitation technique in a confined impinging
jets mixer with the following characteristics: 1 mm inlet tube diameter, 5 mm chamber diameter,
11.2 mm chamber height. The process is sketched in Figure 1: a stream of polymer in organic solvent
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solution is mixed with an anti-solvent, in this case water. The collision of the two jets induces polymer
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Figure 1. Scheme of the process of nanoparticles production by flash nanoprecipitation (FNP).
PCL was dissolved in acetone at concentration from 6 to 25 g/mL and melatonin was dissolved
in the sa e solution at conce tr tions from 4.56 t 36 mg/mL. A complete summary of all formulations
is reported in Tabl 1: in the last column MR, n mely the drug-to-polymer mass ratio, is given.
The proper volu e of acetone solution and anti-solvent were placed in syringes and fed to the CIJM
micro-mixer by a syringe pump (KDS200, KD Scientific, Holliston, MA, USA) at a flow rate from 5 to
120 mL/min. Sample of 8 mL (4 mL for each stream) were taken, collected in a glass vial containing
4 mL of quenching water placed downstream of the mixer; the collected suspension and the quenching
water were kept under magnetic stirring for two minutes and then the nanoparticle suspension was
sent to characterization and analysis.









P6M4.56 4.56 6 0.76
P6M12 12 6 2
P6M18 18 6 3
P6M24 24 6 4
P6M36 36 6 6
P10M4.56 4.56 10 0.456
P10M12 12 10 1.2
P10M18 18 10 1.8
P10M24 24 10 2.4
P10M36 36 10 3.6
P25M4.56 4.56 25 0.1824
P25M12 12 25 0.48
P25M18 18 25 0.72
P25M24 24 25 0.96
P25M36 36 25 1.44
J. Funct. Biomater. 2018, 9, 1 5 of 15
2.3. Nanoparticle Characterization
2.3.1. Dynamic Light Scattering
Size distribution and Zeta potential were measured by means of DLS Zetasizer Nanoseries ZS90,
Malvern Instruments (Malvern, UK). Samples were prepared by diluting 0.1 mL of nanoparticles
suspension in 1 mL of ultrapure water. All samples were measured in triplicate under controlled
temperature at 25.0 ± 0.1 ◦C.
2.3.2. Determination of Loading Capacity (LC) and Encapsulation Efficiency (EE)
Loading capacity was defined as the mass of encapsulated (men) drug divided by the mass of
the whole polymeric nanoparticles system (mtot) as given by Equation (1); it is an indicator of the
amount of drug that can be incorporated in a given amount of nanoparticle formulation. Encapsulation
Efficiency was defined as the amount of encapsulated melatonin over the input quantity of melatonin
in the process (min) as expressed by Equation (2); it is an index of the efficiency of the nanoparticles
production process.
LC = men/mtot (1)
EE = men/min (2)
In order to calculate LC% and EE% the following method based on UV-spectroscopic analysis was
developed. The suspension was placed in a rotary evaporator RE 300 at 50 ◦C, under vacuum for
15 min, to remove acetone; then, it was centrifuged for 10 min at 19,700 g in a SL 16 Thermo scientific
centrifuge and the liquid phase was finally separated from the solid NPs.
The 0.1 mL supernatant sample was diluted in 50 mL of water, filtered through a cellulose syringe
filter of porosity of 0.2 µm and analyzed via UV-Vis spectroscopy. EE% and LC% were calculated
by quantification of free melatonin in the supernatant by mean of a 6850 UV/Vis spectrophotometer,
Jenwa (Stone, Staffordshire, UK). The solid nanoparticles were dried and sent to DSC analysis.
2.3.3. Differential Scanning Calorimetry
Samples of PCL, MEL and MEL-loaded nanoparticles were analyzed by mean of a DSC Q 200 TA
instruments (Milano, Italy). In the case of nanoparticles samples, care was taken to separate them
from the liquid after centrifugation and drying before performing the analysis. The analysis was
conducted in nitrogen atmosphere; samples were stabilized at 20 ◦C and heated to 150 ◦C with a ramp
of 5 ◦C/min.
2.4. Fabric Functionalization
Cotton fabrics were functionalized by imbibition. A volume of 0.5 mL of freshly prepared
nanoparticles suspension was employed for the functionalization of the fabric disk. Each cotton disk
has a 2.5 cm diameter. The suspension was added dropwise, taking care that each drop was completely
absorbed by the fabric and that the colloidal system was uniformly spread all over the surface of the
cotton disk.
After the desired suspension volume was delivered to the fabric, the samples were dried in
standard textile laboratory conditions (21 ◦C and 65% RH) for 8 h.
2.5. Scanning Electron Microscopy
The fabrics surface morphology was examined by a Leica Electron Optics 435 VP scanning
electron microscope (Cambridge, UK) with an acceleration voltage of 15 kV, a current probe of
400 pA and a working distance of 20 mm. The samples were mounted on aluminum specimen stubs
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and sputter-coated with gold in rarefied argon atmosphere using an Emitech K550X Sputter Coater
(Ashford, Kent, UK) with a 20 mA current for 240 s.
2.6. In Vitro Release Test
The in vitro release test from the functionalized fabrics was conducted on static vertical Franz
diffusion cells (PermeGear, Hellertown, PA, USA).
The Franz cells were constituted by an upper donor chamber and a lower receptor chamber
(volume 12 mL) with a contact surface of 1.8 cm2. The acceptor compartment was filled with pH 7.4
phosphate buffer solution kept at temperature of 33 ◦C by a heating jacket.
The skin mimicking membrane was boiled for 60 min to remove the glycerol size and enhance its
wettability; finally, the fabric patches were placed over the membranes in the donor compartment and
sealed over the membrane with a clamp. Samples of the acceptor fluid were withdrawn at a fixed time
interval and analyzed for melatonin by spectrophotometry; after withdrawal, an equal volume of the
fresh PBS solution was replaced into the cell.
2.7. Release Kinetics Modeling
The melatonin release data were fitted by Zeroth-Order, First-Order, Higuchi, Hixon–Crowell,
square root of mass, three seconds root of mass and Baker–Lonsdale models [49,50]. The regression
was performed by interpolating the data of the curve until the asymptote in the cumulative release
was reached.
The determination coefficient was used to discriminate the best fitting model.
The model equations are listed in Table 2 with F denoting the fraction of total drug released up to
time t and k the kinetic constant of each model.
Table 2. Model used to fit release data.
Mathematical Model Equation
Zeroth order F = kt
First order Ln (1 − F) = −kt
Higuchi F = kt1/2
Baker–Lonsdale 3/2[1 − (1 − F)2/3] − F = kt
Hixon–Crowell 1 − (1 − F)1/3 = kt
Square root of mass 1 − (1 − F)1/2 = kt
Three seconds root of mass 1 − (1 − F)2/3 = kt
3. Results and Discussion
3.1. Nanoparticles Size
The particle size is a crucial factor in the design of a transdermal patch; in fact, the particle
diameter differentiates whether the particle will penetrate the epidermis to deliver the drug inside
the skin or whether it will stick to the fabric and elute the active substance from it. To achieve an
effective control on the particle size, the role of key process parameters, namely inlet flow rate, PCL
and melatonin concentration in the impinging stream, were studied.
Only batches presenting mono-modal distribution of NP size, which met instrumentation quality
criteria, were further considered for fabric functionalization.
3.1.1. Effect of Flow Rate
DLS analysis showed that diameter decreased exponentially as the inlet flow rate increases up to a
threshold value of about 80 mL/min, above which the NP size tended to oscillate around an asymptotic
value. Such trend is in accordance with our previous data [29,33,51,52] for loaded and unloaded NPs;
moreover, the same phenomenon has been extensively observed in the literature [27,30].
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To minimize the diameter as required for transdermal applications, further experiments were
conducted at 80 mL/min, namely the threshold value above which NP size was levelled off.
3.1.2. Effect of Melatonin and Polymer Initial Concentration
The NP diameter is plotted against initial melatonin concentration for different initial PCL
concentrations in Figure 2. A linear increase of NP diameter was observed as initial melatonin
concentration increased but this effect was more pronounced as PCL concentration increased; generally
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Figure 2. Particle size versus inlet PCL and melatonin concentration for samples produced at
FR = 80 mL/min.
These trends can be explained consid ring separately th co tribution of the two species.
The addition of melatonin to the formulation caused the particle diameter to increase as a consequence
of the effective incorporation of the drug inside the polymeric system (as discussed in Section 3.3).
On the other hand, increasing PCL concentration made more polymer available during the growth
stage of the nanoparticle, resulting eventually in particles of micrometric size.
3.2. Zeta Potential
The zeta potential for different melatonin concentrations are shown in Figure 3.
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Figure 3. Zeta potential of formulations with PCL 6 mg/mL and different melatonin concentrations
(FR 80 mL/min).
A precise trend cannot be evidenced; however, a slightly more positive charge was observed in
melatonin-loaded NPs with respect to plain PCL NPs. This effect can be explained by observing that
melatonin possesses amine groups, which can undergo protonation in aqueous environment; thus,
the presence of free (not encapsulated) melatonin in the colloidal system can induce the increase of
zeta potential.
3.3. Loading Capacity and Encapsulation Efficiency
LC% and EE% were determined for some selected samples size as summarized Table 3.
Table 3. Loading capacity (LC) and encapsulation efficiency (EE) of selected formulations.
Formulation MR Mean Diameter (nm) LC% EE%
P25M4.56 0.18 852.8 13.0 81.6
P6M4.56 0.76 259.9 39.6 86.2
P25M36 1.44 2316.3 56.4 89.9
P6M36 6 378.1 84.4 90.4
High process yields were always achieved, leading to minimum depletion of active substance
during nanoparticle production. Samples produced with low initial melatonin concentration presented
the lowest EE%. This is not surprising and was ascribed to melatonin aqueous solubility (~2 mg/mL),
which is not negligible. In fact, some melatonin is transferred and dissolved in water during the
flash precipitation process and this amount is in percentage more relevant for low initial melatonin
concentration. Moreover, in the case of low concentration samples, leakage from formed nanoparticles
can also occur. This is also in accordance with the mechanism proposed by Chow [30]. The loading
capacity was instead directly related to the drug-to-polymer mass ratio, allowing to obtain the desired
loading content by designing the formulation.
3.4. Differential Scanning Calorimetry
Thermograms of pure PCL and melatonin were collected as reference. As shown in Figure 4, the
individual peaks of pure PCL and melatonin were observed at 67.13 ◦C and 118.35 ◦C respectively,
while in the case of MEL-loaded nanoparticles a single peak at 55 ◦C appears.
The absence of the active principle peak in the nanoparticle thermograms is commonly
considered a proof that the drug is encapsulated in the nanoparticles and not only outside the
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nanoformations [53,54]. Since the DSC was performed on dried particle separated from supernatant
liquid, the absence of melatonin outside the particles confirms that the increase in zeta potential
discussed in Section 3.2 can be ascribed to free melatonin in the solution. Comparing the two different
DSC scans of Figure 4, it is noticeable the NP peak shift from 55.53 ◦C to 56.29 ◦C for formulation
PCL6MEL36; this phenomenon can be attributed to higher melatonin content in P6M36 formulation in









interaction with  cotton  bean  shaped morphology.  Samples  of  cotton  fabrics  functionalized with 
P25M4.56 are shown  in Figure 5;  the  fibers are covered by polymer aggregates or by particles of 
micrometric size. 
Figure 4. Differential scanning calorimetry (DSC) analysis results for formulation P6M4.56 (top) and
P6M36 (bottom) compared with the raw materials ones.
3.5. Scanning Electron Microscopy
SEM morphological analysis was carried out on functionalized cotton fabrics. The aim was
to check NP adhesion on the fibers and compare NP aggregate size with fiber size, to understand
NP interaction with cotton bean shaped morphology. Samples of cotton fabrics functionalized with
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inside the dip of the typical bean shape cotton fiber, rather than being grafted on the exterior surface. 
Therefore, depending on the particles diameter, different extents of NPs adhesion can be achieved. 






















Figure 5. SEM image of fabric impregnated with formulation P25M4.56, at magnification 500× (left)
and 2000× (right).
In the case of formulation P6M36, Figure 6 shows that the smallest nanoparticles are hosted
inside the dip of the typical bean shape cotton fiber, rather than being grafted on the exterior surface.
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release profiles. Comparing the kinetics of the two l w MEL samples, it can be o served that
P25M4.56 exhibited a slower kinetics, ascribable to the lower LC%, which made MEL diffusion from
NP slower.
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surface area of the system P6M4.56 due to its reduced sizes. In fact, higher surface area means higher
surface from which the drug can be released.
Focusing on the comparison between the samples with higher amount of melatonin, P25M36
and P6M36, is worth of noting that the two systems presented different properties. Firstly, their sizes
were very different: P25M36 was characterized by sizes in the micrometer order, about 2.3 µm, while
the sizes of P6M36 were about 378 nm. It is well-established that a nanoparticles system can offer a
better controlled release than that involving micro-particles. Secondly, P25M36 and P6M36 displayed
different LC%: 56.4 and 84.4%, respectively. Consequently, it is reasonable that the sample P25M36









In conclusion,  the sample P6M36 was  found  to be  the best sample, characterized by  the best 
properties among  all  the prepared  samples,  i.e., a higher LC% value and good particles  sizes.  It 
displayed the best controlled release, acting as drug reservoir system at the skin‐like surface. In fact, 
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Figure 7. Cum lative release curves for t e f ctionalized patches.
In conclusion, the sample P6M36 was found to be the best sample, characterized by the best
properties among all the prepared samples, i.e., a higher LC% value and good particles sizes.
It displayed th best controlled release, acting as drug reservoir system at the skin-like surface.
In fact, the particle sizes of P6M36 was in the order of the membra e c toff. Therefore, the n no arriers
released MEL inside the membrane and then the drug was continuously released from the particles to
the receptor fluid.
The fraction of melatonin released with respect to the amount theoretically loaded on the fabric
are shown in Figure 8. Less than half of the melatonin was released from the carrier: this can be
explained by the fact that, as it was stated in the introduction, PCL is a polymer that biodegrades over
long periods (e.g., several weeks). Thus, PCL NPs act as a drug reservoir on the fabrics.
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Figure 8. A ount of elatonin released ith respect to the theoretical a ount on the fabric.
The release curves were fitted using the semi-empirical models listed in Section 2.7; the correlation
coefficients of every model for the tested formulation are listed in Table 4.
Table 4. Coefficients of determination (R2) values for release data fitting.
Sample ZerothOrder
First





P6M4.56 0.33 0.94 0.88 0.79 0.97 0.69 0.56
P6M36 0.63 0.90 0.97 0.82 0.99 0.77 0.71
P25M4.56 −0.46 0.71 0.65 0.45 0.94 0.28 0.07
P25M36 0.84 0.95 0.98 0.92 0.99 0.91 0.88
It can be observed that the release kinetics of the functionalized systems can be fitted best by
Baker–Lonsdale model, which was developed to describe diffusion controlled drug release from
spherical matrices. This result gives further support to the hypothesis that melatonin was released by
diffusion from the nanoparticles.
4. Conclusions
This work described the design and testing of a transdermal drug delivery device. Melatonin was
encapsulated in PCL by mean of FNP precipitation, with effective control of particle diameter in the
right size for transdermal applications. The encapsulation process was highly efficient and more
than 80% of melatonin was incorporated in the polymer as proven by UV-visible and DSC analysis.
Franz cell experiments demonstrated that the functionalized fabrics were an effective device for
delivering melatonin through skin in a continuous and controlled way. The present research provides
interesting preliminary results about the possibility of administering melatonin through daily worn
garments. Such an administration approach can overcome the side effect of first pass metabolism
occurring in the case of oral administration. Moreover, it represents an improvement with respect to
conventional transdermal systems such as creams and ointments that must be locally applied several
times a day. Once worn next to skin, the fabric can deliver melatonin for several hours without any
further action of the patient to be taken.
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